The CDC issued a well being advisory Thursday recommending that hospitalized sufferers who’ve examined optimistic for influenza be examined for the hen flu virus inside 24 hours.
What To Know: There have been 67 confirmed human circumstances of hen flu within the U.S. since 2024 and the CDC says it is “watching the scenario rigorously and dealing with states to watch individuals with animal exposures.”
The CDC’s newest H5N1 bird flu advisory comes as new circumstances proceed to be revealed. On Wednesday, the CDC confirmed a hen flu an infection in a baby within the San Francisco space who was not hospitalized and has since recovered. The CDC mentioned it’s nonetheless investigating how the kid was uncovered to the virus.
Learn Subsequent: UnitedHealth CEO Highlights Hospitals, Docs, Pharma’s Function In Hovering Well being Care Prices
Based on a Washington Submit report, Nirav Shah, CDC’s principal deputy director, mentioned the newest suggestion is supposed to speed up testing fairly than enhance the variety of checks being carried out.
Shah mentioned it was prompted by circumstances through which contaminated sufferers had been later confirmed to have hen flu, together with after being discharged.
Earlier this month, the Louisiana Division of Well being reported the primary human demise within the U.S. associated to the H5N1 hen flu virus.
Vaccine Makers: Shares of vaccine-related shares are on watch as earlier hen flu developments have triggered shares to spike.
Moderna, Inc. MRNA acquired a $176 million authorities contract in July to advance improvement of its hen flu vaccine, leveraging the identical mRNA know-how used within the firm’s COVID-19 vaccine.
Novavax, Inc. NVAX has a hen flu vaccine in medical trials along with a COVID-19-influenza mixture vaccine in late-stage medical trials.
CureVac N.V. CVAC inventory can be on watch as the corporate has began a section I/II examine on its hen flu vaccine developed in collaboration with GSK plc GSK.
Learn Subsequent:
Photograph: Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
